EP1545572A4 - Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon - Google Patents
Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davonInfo
- Publication number
- EP1545572A4 EP1545572A4 EP02739474A EP02739474A EP1545572A4 EP 1545572 A4 EP1545572 A4 EP 1545572A4 EP 02739474 A EP02739474 A EP 02739474A EP 02739474 A EP02739474 A EP 02739474A EP 1545572 A4 EP1545572 A4 EP 1545572A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell surface
- therapeutic uses
- surface proteases
- conjugates
- activated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29326701P | 2001-05-23 | 2001-05-23 | |
US293267P | 2001-05-23 | ||
PCT/US2002/016819 WO2002095007A2 (en) | 2001-05-23 | 2002-05-23 | Conjugates activated by cell surface proteases and therapeutic uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1545572A2 EP1545572A2 (de) | 2005-06-29 |
EP1545572A4 true EP1545572A4 (de) | 2006-04-12 |
Family
ID=23128397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02739474A Withdrawn EP1545572A4 (de) | 2001-05-23 | 2002-05-23 | Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1545572A4 (de) |
JP (1) | JP2005518332A (de) |
KR (1) | KR20040004642A (de) |
CA (1) | CA2447023A1 (de) |
WO (1) | WO2002095007A2 (de) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7037667B1 (en) | 1998-06-01 | 2006-05-02 | Agensys, Inc. | Tumor antigen useful in diagnosis and therapy of prostate and colon cancer |
EP1544304A4 (de) * | 2002-07-31 | 2006-05-10 | Astellas Pharma Inc | Neue serinprotease |
JP5335191B2 (ja) | 2003-08-22 | 2013-11-06 | デンドレオン コーポレイション | Trp−p8発現に関連する疾患の処置をするための組成物および方法 |
EP1831370A4 (de) | 2004-12-13 | 2009-08-12 | Alethia Biotherapeutics Inc | An der knochenneuformung beteiligte polynukleotide und polypeptidsequenzen |
KR101393946B1 (ko) | 2005-10-21 | 2014-05-12 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 보체 활성화를 억제하는 변형된 프로테아제 |
US7772266B2 (en) | 2006-02-15 | 2010-08-10 | Dendreon Corporation | Small-molecule modulators of TRP-P8 activity |
CN101420942B (zh) | 2006-02-15 | 2014-03-12 | 登德雷恩股份有限公司 | Trp-p8活性的小分子调节剂 |
KR100906145B1 (ko) * | 2006-05-30 | 2009-07-03 | 한국생명공학연구원 | Tmprss4 억제제를 유효성분으로 포함하는 항암제 |
KR101778174B1 (ko) | 2006-07-05 | 2017-09-13 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제 |
FR2906724B1 (fr) | 2006-10-04 | 2009-03-20 | Sanofi Pasteur Sa | Methode d'immunisation contre les 4 serotypes de la dengue. |
TWI465247B (zh) | 2008-04-11 | 2014-12-21 | Catalyst Biosciences Inc | 經修飾的因子vii多肽和其用途 |
EP2353609A1 (de) | 2010-02-04 | 2011-08-10 | Sanofi Pasteur | Immunisierungszusammensetzungen und -verfahren |
US9869021B2 (en) | 2010-05-25 | 2018-01-16 | Aventa Technologies, Inc. | Showerhead apparatus for a linear batch chemical vapor deposition system |
CN103069555B (zh) | 2010-08-18 | 2016-10-26 | 独立行政法人产业技术综合研究所 | 有机半导体薄膜以及有机半导体单晶薄膜的制造方法 |
EP2814807A4 (de) * | 2012-02-16 | 2015-10-07 | Rqx Pharmaceuticals Inc | Lineare peptidantibiotika |
SG11201500412TA (en) | 2012-07-24 | 2015-02-27 | Sanofi Pasteur | Vaccine compositions |
US20150265695A1 (en) | 2012-07-24 | 2015-09-24 | Sanofi Pasteur | Vaccine compositions for prevention against dengue virus infection |
MX365612B (es) | 2012-07-25 | 2019-06-07 | Catalyst Biosciences Inc | Polipeptidos de factor x modificados y usos de los mismos. |
BR112015012515B1 (pt) | 2012-11-30 | 2023-04-11 | Sanofi Pasteur | Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola |
RU2737434C2 (ru) | 2013-03-13 | 2020-11-30 | Форма Терапьютикс, Инк. | Новые соединения и композиции для ингибирования fasn |
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
US10781435B2 (en) | 2017-06-22 | 2020-09-22 | Catalyst Biosciences, Inc. | Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use |
TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
US10793554B2 (en) | 2018-10-29 | 2020-10-06 | Forma Therapeutics, Inc. | Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone |
US20210069306A1 (en) | 2019-08-15 | 2021-03-11 | Catalyst Biosciences, Inc. | Modified factor vii polypeptides for subcutaneous administration and on-demand treatment |
EP3932935A1 (de) * | 2020-06-29 | 2022-01-05 | Centre National de la Recherche Scientifique | Antibakterielle peptide |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036604A2 (en) * | 1999-11-18 | 2001-05-25 | Corvas International, Inc. | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
WO2001068145A2 (en) * | 2000-03-15 | 2001-09-20 | Bristol-Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
WO2003000201A2 (en) * | 2001-06-25 | 2003-01-03 | Drug Innovation & Design, Incorporated | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
WO2003068934A2 (en) * | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
WO2003104394A2 (en) * | 2002-05-21 | 2003-12-18 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972616A (en) * | 1998-02-20 | 1999-10-26 | The Board Of Trustees Of The University Of Arkansas | TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas |
EP1161266A4 (de) * | 1999-03-12 | 2007-09-19 | Univ Georgetown | Matriptase, ein serinprotease, und dessen verwendungen |
WO2003037326A1 (en) * | 2001-10-29 | 2003-05-08 | Corvas International, Inc. | Solid phase synthesis of chemical libraries |
-
2002
- 2002-05-23 CA CA002447023A patent/CA2447023A1/en not_active Abandoned
- 2002-05-23 KR KR10-2003-7015240A patent/KR20040004642A/ko not_active Application Discontinuation
- 2002-05-23 WO PCT/US2002/016819 patent/WO2002095007A2/en not_active Application Discontinuation
- 2002-05-23 EP EP02739474A patent/EP1545572A4/de not_active Withdrawn
- 2002-05-23 JP JP2002592470A patent/JP2005518332A/ja not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001036604A2 (en) * | 1999-11-18 | 2001-05-25 | Corvas International, Inc. | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
WO2001068145A2 (en) * | 2000-03-15 | 2001-09-20 | Bristol-Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
WO2003000201A2 (en) * | 2001-06-25 | 2003-01-03 | Drug Innovation & Design, Incorporated | Exponential pattern recognition based cellular targeting, compositions, methods and anticancer applications |
WO2003068934A2 (en) * | 2002-02-14 | 2003-08-21 | Rutter William J | Chimeric molecules for cleavage in a treated host |
WO2003104394A2 (en) * | 2002-05-21 | 2003-12-18 | Dendreon San Diego Llc | Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon |
Non-Patent Citations (3)
Title |
---|
GARSKY V M ET AL: "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.", JOURNAL OF MEDICINAL CHEMISTRY. 22 NOV 2001, vol. 44, no. 24, 22 November 2001 (2001-11-22), pages 4216 - 4224, XP002355780, ISSN: 0022-2623 * |
MASQUELIER M ET AL: "AMINO ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 1. SYNTHESIS,PHYSICOCHEMICAL PROPERTIES, AND LYSOSOMAL DIGESTION", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 23, no. 11, 1980, pages 1166 - 1170, XP000914522, ISSN: 0022-2623 * |
TAKEUCHI T ET AL: "Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 25 AUG 2000, vol. 275, no. 34, 25 August 2000 (2000-08-25), pages 26333 - 26342, XP002355779, ISSN: 0021-9258 * |
Also Published As
Publication number | Publication date |
---|---|
KR20040004642A (ko) | 2004-01-13 |
EP1545572A2 (de) | 2005-06-29 |
JP2005518332A (ja) | 2005-06-23 |
WO2002095007A2 (en) | 2002-11-28 |
WO2002095007A3 (en) | 2005-05-06 |
CA2447023A1 (en) | 2002-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1545572A4 (de) | Durch zelloberflächenproteasen aktivierte konjugate und therapeutische verwendungen davon | |
EP1463742A4 (de) | Neue pyrazolo- und pyrrolo-pyrimidine und ihre verwendungszwecke | |
GB0028429D0 (en) | Therapy | |
GB0016787D0 (en) | Compounds useful in therapy | |
AU7296801A (en) | Il-17 molecules and uses thereof | |
EP1408978A4 (de) | Neue phenylamino-pyrimidine und ihre verwendungszwecke | |
EP1453837A4 (de) | Zielgerichtete therapeutika und deren anwendungen | |
AU9153601A (en) | Portable sauna | |
IL154553A0 (en) | Urocortin-iii and uses thereof | |
AU2002224553A1 (en) | Human proteases | |
GB0124730D0 (en) | Improvements in or relating to devices | |
AU2001236562A1 (en) | Portable spa | |
GB0010871D0 (en) | Opthalmic injector | |
AU2001229439A1 (en) | Bioconjugates and uses thereof | |
AU2003274402A1 (en) | Fabric column and pad concrete form | |
EP1408985A4 (de) | Neue pyridopyrimidone und ihre verwendungszwecke | |
GB0115780D0 (en) | Therapeutic molecules and uses thereof | |
GB0102717D0 (en) | Cells and uses therefor | |
EP1585971A4 (de) | a-AMYLASE-ASSAY UND VERWENDUNGEN DAVON | |
EP1701736A4 (de) | Therapeutische mittel und ihre verwendungen | |
AUPQ884500A0 (en) | Novel therapeutic molecules and uses therefor - III | |
GB0128167D0 (en) | Improvements in keyboards | |
AU2002304728A1 (en) | Enzymes combination coadjuvating in the interferon therapy | |
AU2001272919A1 (en) | Lp120 polypeptides and therapeutic uses thereof | |
AUPR453501A0 (en) | Improvements in decals |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20031219 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20060228 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060915 |